REFR

Business Context and Reporting Period

Company: Research Frontiers Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Research Frontiers develops and licenses suspended particle device (SPD) technology, often called "light valves," which control light transmission through glass or plastic. The company does not manufacture end products but licenses its technology to third parties (e.g., aircraft window manufacturers, architectural glass producers) who pay royalties (5-10% of net sales) and minimum annual fees. As of March 2003, the company had 13 full-time employees and approximately 365 patents worldwide.

Key Financial Metrics (Year Ended Dec 31, 2002)

Material Changes vs. Prior Period

• Revenue Growth: Fee income increased 53% to $217,519, driven by new license agreements entered in 2002 and minimum annual royalties paid by end-product licensees. A small amount of royalty income was recognized in Q4 2002 from licensee sales exceeding minimums.
• Expense Reduction: Operating expenses decreased by $524,166 (17%) and R&D expenses decreased by $364,395 (16%). Reductions were primarily due to lower payroll, patent, and materials costs. Notably, no performance bonus accruals were made in 2002, whereas $785,500 was accrued in 2001.
• Investment Income Decline: Net investment income dropped 63% to $256,926 due to lower average investment balances, lower interest rates, and a decline in the market value of an equity security.
• Cash Position: Cash and cash equivalents surged by $4.26 million, primarily from the sale of $6.99 million in available-for-sale securities and $3.18 million in proceeds from stock option/warrant exercises. This was partially offset by $3.73 million used for operating activities and $2.35 million used to repurchase and retire common stock.
• Related Party Repayment: Two executive officers repaid loans totaling $152,961 in principal plus accrued interest ($64,608 recorded as interest income) in late 2002.

Outlook, Risks, and Management Commentary

• Liquidity and Capital Resources: Management believes existing cash reserves and budgeted revenues are sufficient to fund operations for the next 15 months without additional financing. However, future funding needs depend on R&D costs, patent filings, and licensee commercialization success.
• Commercialization Status: The company has transitioned from pure R&D to having licensees selling products. InspecTech Aero Service has installed SPD windows on various aircraft (Airbus, Boeing, Gulfstream). Hankuk Glass Industries' subsidiary, SPD Inc., began production of SPD film in early 2002.
• Risks:
  • Dependence on Licensees: Success depends entirely on licensees' ability to commercialize products and pay royalties. The company has no backlog of orders itself.
  • Competition: Faces competition from established technologies like electrochromic and liquid crystal devices, as well as large corporations (3M, Gentex, PPG) with greater resources.
  • Patent Validity: While holding ~365 patents, their validity has never been contested in litigation.
• Corporate Actions: In February 2003, the Board adopted a Stockholders' Rights Plan (Poison Pill) triggered at 15% ownership. The company also terminated its 2002 performance bonus plan, replacing it with a general bonus plan capped at $300,000 aggregate for 2003.

Investor Verification Checklist

• Licensee Sales Volume: Verify if licensees (e.g., InspecTech, Hankuk Glass) are generating sufficient sales volume to trigger royalties above minimum annual payments, as fee income remains low relative to operating costs.
• Cash Burn Rate: Confirm the 15-month runway estimate given the continued net loss of ~$4 million annually and the cessation of the Ailouros Ltd. financing commitment (expired Dec 2001, extended to Dec 2003 but not guaranteed).
• Stock Repurchase Impact: Review the rationale for repurchasing $2.35 million of stock while the company is unprofitable and burning cash.
• Investment Portfolio: Assess the remaining $11,250 in marketable securities and the risk of further impairment charges on the equity security held.
• Patent Expirations: Monitor the expiration schedule of the 27 U.S. patents (expiring 2006-2021) and foreign patents to ensure continued protection of the core technology.